siRNA design and galNAc-empowered hepatic targeted delivery

Mei Lu, Mengjie Zhang, Bo Hu, Yuanyu Huang*

*Corresponding author for this work

Research output: Chapter in Book/Report/Conference proceedingChapterpeer-review

6 Citations (Scopus)

Abstract

Small interfering RNA (siRNA) is a clinically approved therapeutic modality, which has attracted widespread attention not only from basic research but also from pharmaceutical industry. As siRNA can theoretically modulate any disease-related gene’s expression, plenty of siRNA therapeutic pipelines have been established by tens of biotechnology companies. The drug performance of siRNA heavily depends on the sequence, the chemical modification, and the delivery of siRNA. Here, we describe the rational design protocol of siRNA, and provide some modification patterns that can enhance siRNA’s stability and reduce its off-target effect. Also, the delivery method based on N-acetylgalactosamine (GalNAc)-siRNA conjugate that is widely employed to develop therapeutic regimens for liver-related diseases is also recapitulated.

Original languageEnglish
Title of host publicationMethods in Molecular Biology
PublisherHumana Press Inc.
Pages77-100
Number of pages24
DOIs
Publication statusPublished - 2021

Publication series

NameMethods in Molecular Biology
Volume2282
ISSN (Print)1064-3745
ISSN (Electronic)1940-6029

Keywords

  • GalNAc
  • Nucleic acid therapeutic
  • RNA interference
  • RNAi
  • siRNA delivery
  • siRNA design
  • siRNA modification

Fingerprint

Dive into the research topics of 'siRNA design and galNAc-empowered hepatic targeted delivery'. Together they form a unique fingerprint.

Cite this